COMMUNIQUÉS West-GlobeNewswire

-
PharmAla Launches MDMA Clinical Trial Tool for Researchers
22/08/2024 -
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
22/08/2024 -
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
22/08/2024 -
Aviv Clinics Congratulates Peter Paltchik on Winning Bronze at the 2024 Paris Olympics
22/08/2024 -
Thomas L. Tran, Former Chief Financial Officer of Molina Healthcare, Joins Clover Health’s Board of Directors
22/08/2024 -
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
22/08/2024 -
Asensus Surgical Announces Closing of Acquisition by KARL STORZ
22/08/2024 -
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
22/08/2024 -
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
22/08/2024 -
TOMI Environmental Solutions Expands Partnership With A Global Leader in Laboratory Services
22/08/2024 -
Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
22/08/2024 -
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
22/08/2024 -
Stryker announces definitive agreement to acquire Vertos Medical, Inc., expanding interventional pain management solutions
22/08/2024 -
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
22/08/2024 -
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
22/08/2024 -
Starton Therapeutics Strengthens Clinical Development Strategy Following Successful Scientific Advisory Board Meeting at ASCO 2024
22/08/2024 -
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
22/08/2024 -
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
22/08/2024 -
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/08/2024
Pages